Cellular and molecular pathways linking inflammation and cancer
C Porta, P Larghi, M Rimoldi, MG Totaro, P Allavena… - Immunobiology, 2009 - Elsevier
Several experimental and epidemiological evidence indicate that, irrespective of the trigger
for the development (chronic infection/inflammation or genetic alteration), a “smouldering” …
for the development (chronic infection/inflammation or genetic alteration), a “smouldering” …
Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases
AL Hardaway, MK Herroon, E Rajagurubandara… - Cancer and Metastasis …, 2014 - Springer
Adipocytes are important but underappreciated components of bone marrow
microenvironment, and their numbers greatly increase with age, obesity, and associated …
microenvironment, and their numbers greatly increase with age, obesity, and associated …
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 …
JY Pierga, S Delaloge, M Espié, E Brain… - Breast cancer research …, 2010 - Springer
To assess anti-tumor activity of sequential epirubicin/cyclophosphamide followed by
docetaxel with the randomized addition of celecoxib in HER2 negative patients or …
docetaxel with the randomized addition of celecoxib in HER2 negative patients or …
Premetastatic soil and prevention of breast cancer brain metastasis
Y Liu, A Kosaka, M Ikeura, G Kohanbash… - Neuro …, 2013 - academic.oup.com
Background As therapies for systemic cancer improve and patients survive longer, the risk
for brain metastases increases. We evaluated whether immune mechanisms are involved in …
for brain metastases increases. We evaluated whether immune mechanisms are involved in …
Metformin suppresses breast cancer growth via inhibition of cyclooxygenase‑2
B Shi, X Hu, H He, W Fang - Oncology Letters, 2021 - spandidos-publications.com
Pre‑clinical and on‑going trials have indicated the advantage of using metformin as an
anticancer drug alone or in combination with other chemotherapeutics for the treatment of …
anticancer drug alone or in combination with other chemotherapeutics for the treatment of …
Prognostic histopathological and molecular markers in feline mammary neoplasia
K Hughes, JM Dobson - The Veterinary Journal, 2012 - Elsevier
Feline mammary tumours comprise approximately 11% of feline non-integumentary
neoplasms, are more commonly malignant than benign, and carry a poor prognosis …
neoplasms, are more commonly malignant than benign, and carry a poor prognosis …
The role of inflammation in breast and prostate cancer metastasis to bone
A Göbel, S Dell'Endice, N Jaschke, S Pählig… - International Journal of …, 2021 - mdpi.com
Tumor metastasis to bone is a common event in multiple forms of malignancy. Inflammation
holds essential functions in homeostasis as a defense mechanism against infections and is …
holds essential functions in homeostasis as a defense mechanism against infections and is …
The efficacy and safety of celecoxib in addition to standard cancer therapy: a systematic review and meta-analysis of randomized controlled trials
SY Ye, JY Li, TH Li, YX Song, JX Sun, XW Chen… - Current …, 2022 - mdpi.com
The purpose of this meta-analysis was to evaluate the efficacy and safety of celecoxib, a
selective cyclooxygenase-2 (COX-2) inhibitor, in addition to standard anticancer therapy …
selective cyclooxygenase-2 (COX-2) inhibitor, in addition to standard anticancer therapy …
COX2 overexpression is a prognostic marker for Stage III breast cancer
To determine the significance of (Cyclooxygenase 2) COX2 for clinical outcome in breast
cancer, we analyzed the correlation between COX2 overexpression and survival in 687 …
cancer, we analyzed the correlation between COX2 overexpression and survival in 687 …
Anti-inflammatory phytochemicals for chemoprevention of colon cancer
Every year more than a million new cancer cases and 600,000 deaths are reported world-
wide. Colorectal cancer is the fourth most commonly occurring and second leading cause of …
wide. Colorectal cancer is the fourth most commonly occurring and second leading cause of …